GALT, US3632252025

Galectin Therapeutics stock gets a Phase 3 protocol update

Published on 10/07/2026 at 01:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galectin Therapeutics stock gets a Phase 3 protocol update after the company submitted its registrational plan to the FDA on October 6, 2026. The shares were last at USD 3.73 on Nasdaq after a 4.36 percent decline.

GALT, US3632252025, Illustration mit AI erstellt.

Galectin Therapeutics Inc. (ISIN US3632252025) was last at USD 3.73 on Nasdaq on October 5, 2026, down 4.36 percent from the previous close. The company submitted a registrational Phase 3 protocol for belapectin to the FDA and scheduled three data presentations for the AASLD Liver Meeting, according to Galectin Therapeutics on October 6, 2026.

Phase 3 protocol reaches FDA

The filing covers a Phase 3 trial intended to study belapectin in patients with MASH cirrhosis and portal hypertension. The company will present analyses from the NAVIGATE and GT-026 Phase 2b trials at the liver meeting in Denver from November 5 to November 9, 2026, including one oral presentation and two posters.

The timing gives GALT a defined clinical checkpoint after the protocol submission. The oral presentation is scheduled for November 8, 2026, while a Poster of Distinction is scheduled for November 7, 2026, according to GlobeNewswire on October 6, 2026.

Q2 loss widens to USD 9.113 million

Galectin's fiscal Q2 2026 net loss was USD 9.113 million, compared with USD 7.521 million in fiscal Q2 2025. Diluted loss per share was USD 0.14 versus USD 0.12 in the prior-year quarter, according to Canli Capital in its review of the August 14, 2026 10-Q filing.

The six-month comparison is less negative on the earnings line: net loss improved to USD 14.159 million from USD 17.152 million in the first half of 2025. Operating cash flow also improved to negative USD 6.305 million from negative USD 14.291 million, but cash and cash equivalents stood at USD 13.269 million on June 30, 2026, below USD 17.720 million at December 31, 2025.

Stock remains below yearly high

GALT's October 5 reference price was 47.7 percent below the 52-week high of USD 7.13 and 83.7 percent above the 52-week low of USD 2.03. The market capitalization was USD 247.6 million and trading volume was 277,930 shares as of October 6, 2026.

The next corporate checkpoint is the virtual annual meeting on December 3, 2026. The preliminary proxy asks shareholders to vote on increasing authorized common shares from 150,000,000 to 250,000,000 and reserving 3,000,000 additional equity-plan shares, according to StockTitan in the October 2, 2026 proxy filing.

GALT trades at USD 3.73

Galectin Therapeutics stock was last at USD 3.73 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, with the next valuation question tied to the FDA protocol and the November liver meeting.